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Abstract
Background: The BRCA1 and BRCA2 mutation spectrum and mutation detection rates according to different family
histories were investigated in 521 subjects from 322 unrelated Slovenian cancer families with breast and/or ovarian
cancer.
Methods: The BRCA1 and BRCA2 genes were screened using DGGE, PTT, HRM, MLPA and direct sequencing.
Results: Eighteen different mutations were found in BRCA1 and 13 in BRCA2 gene. Mutations in one or other gene
were found in 96 unrelated families. The mutation detection rates were the highest in the families with at least
one breast and at least one ovarian cancer - 42% for BRCA1 and 8% for BRCA2. The mutation detection rate
observed in the families with at least two breast cancers with disease onset before the age of 50 years and no
ovarian cancer was 23% for BRCA1 and 13% for BRCA2. The mutation detection rate in the families with at least
two breast cancers and only one with the disease onset before the age of 50 years was 11% for BRCA1 and 8% for
BRCA2. In the families with at least two breast cancers, all of them with disease onset over the age of 50 years, the
detection rate was 5% for BRCA2 and 0% for BRCA1.
Conclusion: Among the mutations detected in Slovenian population, 5 mutations in BRCA1 and 4 mutations in
BRCA2 have not been described in other populations until now. The most frequent mutations in our population
were c.181T > G, c.1687C > T, c.5266dupC and c.844_850dupTCATTAC in BRCA1 gene and c.7806-2A > G, c.5291C > G
and c.3978insTGCT in BRCA2 gene (detected in 69% of BRCA1 and BRCA2 positive families).
Background
Breast cancer represents 20.7% of all malignancies in
females and is the most frequent type of cancer in the
Slovenian female population. In 2007, 1147 new breast
cancer cases were registered in Slovenia. The incidence
rate among Slovenian women was 112/100000 and is
slowly increasing. Breast and ovarian cancers together
represent as much as 23.9% of all cancers in Slovenian
females [1]. The majority of these two types of cancer
are sporadic and only a small proportion (5%-10%) is
known to be caused by dominantly inherited susceptibil-
ity genes [2]. The BRCA1 and BRCA2 genes were found
to be mutated in a large number of families with multi-
ple cases of an early onset of breast and ovarian cancer
[3-6]. Mutations in BRCA1 and BRCA2 are highly pene-
trant and confer an increased risk of breast and ovarian
cancer in carriers [7-9]. The cumulative breast cancer
risk for BRCA1 and BRCA2 mutation carriers at the age
of 70 was, in different studies, reported to be between
36% and up to 71% [10,11]. The studies of the Breast
Cancer Linkage consortium based on the families with
four or more cancer cases reported an approximate
breast cancer risk of 80% at the age of 70 for mutation
carriers [7,8,12]. The reported cumulative risk for ovar-
ian cancer in BRCA1 and BRCA2 carriers at the age of
70 was 39% to 60% and 22% to 27%, respectively
[8,13,14].
Up to now, several comprehensive studies performed
throughout Europe determined the mutation profiles of
BRCA1 and BRCA2 in families with history of breast
and ovarian cancer. One of the largest studies carried
out by a German consortium included 989 unrelated
families with a history of breast and ovarian cancer who
were screened for mutations in BRCA1 and BRCA2. The
frequency of detected mutations in this study varied from
14% to 50% according to different family histories [15].
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any medium, provided the original work is properly cited.Another large study included 1010 unrelated families from
the Czech Republic with an overall mutation detection
rate of 29% for BRCA1 and BRCA2 [16]. A similar study
was performed in the Dutch population which included
517 unrelated families, where an overall mutation detec-
tion of 23% was reported [17]. In French, Swedish and
Finnish populations, 100 to 200 families were screened
for BRCA1 or BRCA2 mutations [18-20]. The mutation
detection rates in these studies varied from 10 to 25%.
A higher mutation detection rate of 33% was observed in
the study which included 42 Belgian families [21,22].
A comparably high overall mutation detection rate of
30% was reported also among 102 Spanish families [23].
In the Austrian population, the mutation detection rate
was reported to be 20% for BRCA1 among 86 breast and
ovarian cancer families [24]. In Italy, several reports were
published. The overall mutation detection rate for
BRCA1 and BRCA2 in these reports varied from 8 to
37% [25-29].
Slovenia is a country located in the central European
area with approximately 2 million inhabitants. Since
1999, genetic counseling and testing for hereditary breast
and ovarian cancer have been offered at the Institute of
Oncology Ljubljana. Until now, approximately 1100 indi-
viduals have attended genetic counseling and 521 indivi-
duals from 322 families opted for genetic testing.
With this article, we wanted to present the BRCA1
and BRCA2 mutation spectrum and mutation detection
rates according to different family histories in Slovenian
the population.
Methods
Tested individuals
521 persons from 322 Slovenian families with breast
and/or ovarian cancer underwent genetic testing. When
possible, the proband tested for the presence of muta-
tion in BRCA1 and BRCA2 g e n e si nt h ef a m i l yw a st h e
youngest individual affected by breast or ovarian cancer.
All tested individuals provided written informed consent
and attended genetic counseling sessions before and
after testing.
All tested individuals were classified according to their
family history. The family history data were verified in
the Slovenian state cancer registry established in 1950.
The enrolled families were divided into 6 different
groups according to the following criteria:
Group A: Families with two or more cases of breast
cancer among first-degree relatives, including at least
two cases with the disease onset under the age of 50,
with no ovarian cancer.
Group B: Families with one or more cases of breast
and at least one ovarian cancer among first-degree
relatives.
Subgroup BA - families with at least one ovarian
cancer and at least two breast cancers under the age
of 50;
Subgroup BC - families with at least one ovarian
cancer and at least two breast cancers, one under
the age of 50;
Subgroup BD - Families with at least one ovarian
cancer and at least two breast cancers, all beyond
the age of 50;
Subgroup 1B+1O - Families with only one ovarian
cancer and one breast cancer in the family or only
one affected individual in the family, but having
both types of cancer at the same time;
Subgroup more O+1B - Families with at least two
ovarian cancers and only one breast cancer;
Subgroup only O - Families with at least two ovarian
cancers and no breast cancer;
Group C: Families with two or more cases of breast
cancer among first-degree relatives, including one case
diagnosed before the age of 50 and no ovarian cancer.
Group D: Families with two or more cases of breast
cancer among first-degree relatives, all diagnosed
beyond the age of 50 and no ovarian cancer.
Group E: Families with a single case of female breast
cancer diagnosed under the age of 40.
Group MBR: Families with a single breast cancer
among first-degree relatives being the male breast
cancer.
Bilateral breast cancers were counted as two indepen-
dent cases of breast cancer.
Controls: The control group consisted of healthy
volunteers, females aged from 50 to 69 years without
any familial and personal history of breast and/or ovar-
ian cancer who were tested for the presence of all muta-
tions, unclassified variants (UV) and polymorphisms
found in patients.
Mutation screening
The DNA was isolated from peripheral blood using the
DNA blood isolation kit (Qiagen, Hilden, Germany).
Mutation screening in BRCA1 and BRCA2 genes was
performed by two laboratories - the Laboratory of Mole-
cular Oncology at the Vrije University Brussels, Belgium
and the Laboratory of Molecular Diagnostics at the
Institute of Oncology Ljubljana, Slovenia.
All samples were, at the beginning, tested for six most
frequent mutations in the Slovenian population (c.7806-
2A > G in BRCA2, c.5266dupC, c.1687C > T, c.191G >
A, c.181T > G, c.181T > A in BRCA1) [30,31].
I nt h eL a b o r a t o r yo ft h eV r i j eU n i v e r s i t yB r u s s e l s ,
screening for six most frequent mutations was done by
denaturing gradient gel electrophoresis (DGGE) for
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Ai nBRCA1 and c.7806-2A > G in BRCA2 and by protein
truncation test (PTT) for mutation c.1687C > T in
BRCA1. The additional screening of BRCA1/2 was per-
formed with PTT (screening of exon 11 in BRCA1 and
exons 10 and 11 in BRCA2) and DGGE (the rest of exons
of BRCA1 and BRCA2) [21].
I nt h eL a b o r a t o r yo ft h eI n s t i t u t eo fO n c o l o g yL j u b l -
jana, screening for six most frequent mutations was
done using fluorescent hybridization probes on Light
Cycler 2.1 for c.5266dupC, c.1687C > T, c.191G > A,
c.181T > G in BRCA1, high-resolution melting - HRM
on Light Cycler 480 II (Roche Molecular Biochemicals,
Mannheim, Germany) for c.181T > A in BRCA1 and
restriction length polymorphism for c.7806-2A > G in
BRCA2 [30,31]. The additional screening of BRCA1/2
was performed with DGGE.
In both laboratories, the DGGE was performed using
primers designed by Ingeny and according to the manu-
facturer’si n s t r u c t i o n s( I n g e n yI n t e r n a t i o n a lB V ,G o e s ,
Netherlands).
Samples presenting migration abnormalities were
further sequenced on the automated sequence analyzer
ABI310 (Applied Biosystems, USA) (using the BDT v.1.1
and performing the labeling PCR reaction) according to
manufacturer’s instructions. The samples were screened
for the presence of large deletions and duplications
using the multiplex ligation-dependent probe amplifica-
tion MLPA kit (MRC Holland, Amsterdam, Nether-
lands). For BRCA1 gene, the MLPA analysis was
performed with probe set P002 and confirmed by probe
set P087, and for BRCA2 with probe set P045-B1. The
deletion breakpoints were not characterized at the
sequence level.
The description of nucleotide sequence variations is in
accordance with HGVS nomenclature, and in tables,
also in accordance with BIC nomenclature [32,33].
According to HGVS nomenclature DNA variants are
numerated according to NCBI reference sequence
NM_007294.2 for BRCA1, NM_000059.3 for BRCA2.
The first nucleotide of the start codon ATG is numer-
ated as 1. According to BIC nomenclature, DNA var-
iants are numerated according to NCBI reference
sequence HSU14680 for mRNA of BRCA1, or U43746
for mRNA of BRCA2. The first nucleotide of mRNA is
numerated as 1.
Statistical analysis was performed using the Chi-square
test.
Results
The study was performed on 521 individuals from 322
Slovenian breast and/or ovarian cancer families. In 96
families, either the mutation in BRCA1 or the mutation
in BRCA2 was detected. The overall mutation detection
rate for BRCA1 and BRCA2 genes was 29.8% (96/322).
Thus, in 226 families, we found no pathogenic mutation
in either of the two investigated genes.
BRCA1 mutation spectrum
In BRCA1, 18 different deleterious mutations were
found in 68 families (Table 1). The four most common
mutations (c.181T > G, c.1687C > T, c.5266dupC and
c.844_850dupTCATTAC) were detected in 44 families
(65%). The additional 14 mutations in BRCA1 appeared
in other 24 families.
Four of the mentioned 18 mutations are missense
mutations affecting the 5’RING domain (c.116G > A,
c.181T > G, c.181T > A, c.191G > A), three are nonsense
mutations (c.1687C > T, c.5251C > T and c.5377A > T),
seven are frame-shift mutations (c.457_458delAG,
c.844_850dupTCATTAC, c.843_846delCTCA, c.2269-
delG, c.3018_3021delTTCA, c.5177_5180delGAAA and
c.5266dupC) and four are deletions of the whole exons
(Ex1-2 del, Ex5-7 del, Ex5-8 del and Ex5-10 del).
The most common mutation found in BRCA1 gene
was c.181T > G. It was detected in 15 families. The
patients with ovarian cancer represented 36% of all
breast and ovarian cancer cases in the families bearing
the mutation c.181T > G. The average age of the
patients at the onset of ovarian cancer was 52.1 years
and the average age of the patients at the onset of breast
cancer was 48.1 years in these families, respectively.
Breast cancer was, in these families, in 56% of cases
detected before the age of 50. In five families, colorectal
cancer, and in two families, cancers of the uterus, were
also reported in the family history (46% of c.181T > G
families have the HNPCC (hereditary non-polyposis
colon cancer) related cancers in their family history).
The second most common mutation in BRCA1 gene
in Slovenian families with breast and/or ovarian cancer
was c.1687C > T. This mutation was observed in 13
families. The patients with ovarian cancer represented
32% of all breast and ovarian cancer cases in the
families bearing the mutation c.1687C > T. In these
families the average age of the patients at the onset of
ovarian cancer was 52.5 years and the average age of
the patients at the onset of breast cancer was 46.0. In
these families, in 53% of cases, breast cancer was
detected before the age of 50.
The mutation c.5266dupC in BRCA1 gene was
detected in 8 families. The patients with ovarian cancer
represented just 9% of all breast and ovarian cancer
cases in the families bearing the c.5266dupC mutation
since it was diagnosed in merely 2 cases (onset at 50
and 48 years, respectively). The average age of the
patients at the onset of breast cancer in these families
was 37.3 years. In more than 89% of cases, breast cancer
was diagnosed before the age of 50.
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gene was noticed in 8 families. The patients with ovar-
ian cancer represented 30% of all breast and ovarian
cancers cases in the families bearing the mutation
c.844_850dupTCATTAC. The average age of the
patients at the onset of ovarian cancer was 53.7 years,
while the average age of the patients at the onset of
breast cancer was 47.5 years. In 69% of cases, breast
cancer was diagnosed before the age of 50.
BRCA2 mutation spectrum
The analysis of the BRCA2 gene revealed 13 different
mutations in 28 families (Table 2). The most common
mutation in BRCA2 gene is a splice site mutation
c.7806-2A > G. It was detected in 11 families (which
represents 39% of all BRCA2 positive families). The
remaining 12 BRCA2 mutations were much less fre-
quent in the Slovenian population (each being discov-
ered in 1 to 4 families) (Table 2). They are nonsense
mutations or frame-shift mutations causing a truncation
of the encoded protein. No large deletions were found
in the BRCA2 gene.
The c.7806-2A > G mutation was observed in 11
families. The patients with ovarian cancer (three patients
aged 50, 59 and 70 years at the onset of disease) repre-
sented only 6% of all breast and ovarian cancer cases in
the families bearing the mutation c.7806-2A > G. The
average age of the patients at the onset of breast cancer
was 50.9 years. Breast cancer was in 40% of cases dis-
covered before the age of 50.
The second most frequent mutation in BRCA2 gene
was c.5291C > G. It was detected in four families. The
average age of the patients at the onset of breast cancer
in these families was 45.5 years. In 72% of cases, breast
cancer was discovered before the age of 50 years. No
ovarian cancers were observed in these families.
The third most common mutation in BRCA2 gene
occurring in three families was c.3975_3978dupTGCT.
Table 1 Mutations in BRCA1 gene in Slovenian population
BIC
nomenclature*
HGVS
nomenclature**
Protein change
according to BIC
database
Described in BIC
database (No. of
quotations in BIC)
Present in other than Slovenian
population (No. of families) ***
No. of positive
Slovenian
families
235G > A c.116G > A C39Y yes (4) 3
300T > G c.181T > G C61G yes (202) Germany (30), Italy (?), Czech rep (20),
Austria (3), Slovakia (2)
15
300T > A c.181T > A C61S no 4
310G > A c.191G > A C64Y yes (20) Germany (1), Czech rep (1), Canada
(2)
1
576delAG c.457_458delAG 157X no 1
963-969 dup
(969ins7)
c.844_850dupTCATTAC 288X yes (2) Germany (2) 8
962 del4 c.843_846delCTCA 297X yes (17) Germany (2), Italy (?), Czech rep (1),
Austria (2), Slovakia (2), Canada
(2- Slavic origin)
2
1806C > T c.1687C > T Q563X yes (88) Germany (5), Czech rep (6), Austria (2) 13
2388delG c.2269delG 764X yes (7) 1
3137delTTCA c.3018_3021delTTCA 1022X yes (2) 1
5296 del4
(GAAA)
c.5177_5180delGAAA 1728X yes (45) 1
5370C > T c.5251C > T R1751X yes (30) Germany (1), 1
5382insC c.5266dupC 1829X yes (200) Germany (46), Italy (?), Czech rep. (75),
Netherlands (5), Austria (2), Slovakia (2)
8
5496A > T c.5377A > T K1793X no 2
Ex1-2del Ex1-2del no Germany (?),Czech (1) Canada, Spain 1
Ex5-10 del Ex5-10 del no 3
Ex5-8 del Ex5-8 del no 1
Ex5-7 del Ex5-7 del no Spain, Germany 2
Total BRCA1 68
Description of nucleotide variations is in accordance with *BIC nomenclature (DNA variants are numerated according to NCBI reference sequence HSU14680 for
mRNA of BRCA1; the first nucleotide of mRNA is numerated as 1) or **HGVS nomenclature (DNA variants are numerated according to NCBI reference sequence
NM_007294.2 for BRCA1; the first nucleotide of the start codon ATG is numerated as 1).
*** References: Spain [23,44]. Czech Rep [16,45]. Germany [15,46]. Italy [15]. Netherlands [17]. Austria [24]. Slovakia [47]. Canada [48].
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“ovarian cluster region” of BRCA2 gene [34,35]. The
patients with ovarian cancer( t w op a t i e n t sa g e d4 0a n d
52 years at the onset of the disease) represented 29% of
all breast and ovarian cancer cases in these families. The
average age of the patients at the onset of breast cancer
was 52.2 years. In 66% of cases, breast cancer was
detected before the age of 50 years.
Polymorphisms and unclassified sequence variants in
BRCA1 and BRCA2 genes
All sequence variants which were not classified as muta-
tions were categorized either as polymorphisms or as
unclassified variants (UVs) according to the BIC database
(Breast cancer information core) (Tables 3, 4 and 5). When
the sequence variant was not reported in the BIC database,
we classified it as a UV. Polymorphisms detected in indivi-
duals with breast and ovarian cancer family history and
those found in the control group are listed in Table 3,
while unclassified variants are given in Tables 4 and 5.
Unclassified variants were more common in BRCA2 (20
different UVs) than in BRCA1 (12 different UV) (Tables 4
and 5). Most UVs are missense mutations, yet two UVs in
the BRCA2 gene cause frame-shift of the open reading frame.
Controls
The DNA of 40 healthy Slovenian women aged
between 50 and 69 years without any personal and
familial breast and/or ovarian cancer history was also
tested for the presence of all known mutations, UVs
and polymorphisms in BRCA1 and BRCA2 genes in
Slovenian population. The results are given in the
Tables 2 and 3. No mutations were detected in the
control group. All frequent polymorphisms observed in
individuals with breast and ovarian cancer family his-
tory, with the allele frequency of more than 2%, were
detected also in the control group with similar allele
frequencies (Table 3).
Mutation detection rates
The mutation detection rates in different groups and
subgroups defined according to the familial cancer his-
tory are presented in Tables 6 and 7.
To estimate the influence of number of breast cancer
cases in the family on the mutation detection rate
among the families with only breast cancer history, we
subdivided Groups A, C and D according to the number
of breast cancer cases in the family. The proportions of
families with 2, 3 or 4 breast cancers were relatively
similar in all three groups (Table 8).
The frequency at which BRCA1 and BRCA2 gene muta-
tions were detected in the families belonging to Group B
was statistically significantly higher when compared to
Groups A, C, D, E and MBR (p-values: 0.034, 0.021, 0.008,
0.006, 0.003, respectively). Also the frequency of mutations
seen in Group A was statistically significantly different
Table 2 Mutations in BRCA2 gene in Slovenian population
BIC
nomenclature*
HGVS
nomenclature**
Protein change
according to BIC
database
Described in BIC
database (No. of
quotations in BIC)
Present in other than
Slovenian population (No. of
families) ***
No. of positive
Slovenian
families
1003A > T**** c.775A > T R259X no 1
1756G > T c.1528G > T E510X yes (1) 1
2041insA c.1813dupA 615X yes (97) Germany (5), Czech rep (2) 1
3493C > T c.3265C > T Q1089X yes (1) 1
4206 ins4
(TGCT)
4203_4206dupl
c.3978insTGCT
c.3975_3978dupTGCT
1330X yes 3
5164delGAAA c.4936_4939delGAAA 1668X yes 1
5519C > G c.5291C > G S1764X no 4
5579insA c.5351insA c.5351dupA 1786X yes Netherland (6) 1
5837TC > AG c.5609_5610delTCinsAG F1870X yes (2) 1
6719delAGTT c.6491_6494delAGTT 2166X no 1
7531C > T c.7303C > T Q2435X no 1
IVS16-2A > G
8064-2A > G
c.7806-2A > G aberrant splicing yes (5) Germany (2 ), Italy (2) 11
9514C > T c.9286C > T E3096X yes (1) no 1
Total 28
Description of nucleotide variations is in accordance with BIC nomenclature* (DNA variants are numerated according to NCBI reference sequence U43746 for
mRNA of BRCA2; the first nucleotide of mRNA is numerated as 1) or HGVS nomenclature** (DNA variants are numerated according to NCBI reference
NM_000059.3 for BRCA2; the first nucleotide of the start codon ATG is numerated as 1). ***References: Germany [15]. Italy [15]. Czech Rep [16,45]. Netherland
[17]. ****Albanian origin - Kosovo.
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tively (p-values < 0.001 in all four cases) (Table 6).
Discussion
Genetic counseling and testing of individuals from
families with an increased risk of breast and/or ovarian
cancer in Slovenia has been available at the Institute of
Oncology Ljubljana since 1999. From then and until
January 2009, we screened 322 families and we detected
ah i g h l yp e n e t r a n tBRCA1 and BRCA2 mutation in
96 of them. In this study, we are summarizing the most
significant features of hereditary breast and ovarian can-
cer in Slovenian families. The overall mutation detection
rate in our series was 21.1% for BRCA1 and 8.7% for
BRCA2; for both genes, it was 29.8%.
In general, the mutation detection rates for BRCA1
and BRCA2 genes in the members of Slovenian families
with breast and/or ovarian cancer are comparable with
the mutation frequencies in these two genes reported
for other countries [15,17,25]. When comparing the
study groups, the highest mutation detection rate in Slo-
venian population was observed in the families with at
least one breast and at least one ovarian cancer (Group B)
- 42% for BRCA1 and 8% for BRCA2 or 50% for both
genes (Table 6). Similar mutation detection rates for
families with the same characteristics were reported in
Table 3 Polymorphisms in BRCA1 and BRCA2 genes in Slovenian population
BIC
nomenclature*
HGVS
nomenclature**
Protein
change
Allele No. of alleles/all
alleles of tested
probands (allele
frequencies)
No. of alleles/all alleles of
tested healthy individuals
(allele frequencies)
Described
in BIC
database
Clinical importance
entered in BIC
database (allele
frequencies)
BRCA1
710 C > T c.591C > T C197C T 1/380 (0.003) 0/80 (0.000) yes no (0.02)
1186A > G c.1067A > G Q356R G 25/380 (0.065) 6/80 (0.075) yes no (0.06)
2196G > A c.2077G > A D693N A 6/208 (0.029) 4/80 (0.050) yes no (0.08)
2201C > T c.2082C > T S694S T 66/208 (0.32) 25/80 (0.31) yes no (0.31)
2430T > C c.2311T > C L771L C 66/208 (0.32) 25/80 (0.31) yes no (0.31)
2731C > T c.2612C > T P871L T 66/208 (0.32) 25/80 (0.31) yes no (0.34)
3232A > G c.3113A > G E1038G G 66/208 (0.32) 25/80 (0.31) yes no (0.31)
3667A > G c.3548A > G K1183G G 66/208 (0.32) 25/80 (0.31) yes no (0.31)
4427T > C c.4308T > C F1436S C 66/208 (0.32) 25/80 (0.31) yes no (0.31)
4956A > G c.4837A > G S1613G G 66/208 (0.32) 25/80 (0.31) yes no (0.31)
BRCA2
203G > A c.1-25G > A 5’-UTR A 66/208 (0.32) 25/80 (0.31) yes no (0.25)
1093A > C c.865A > C N289H C 18/380 (0.047) 3/80 (0.038) yes no (?)
1342C > A c.1114C > A H372N A 160/208 (0.77) 56/80 (0.70) yes no (0.72)
1379C > T c.1151C > T S384F T 1/208 (0.005) 0/80 (0.000) yes no (?)
1593A > G c.1365A > G S455S G 7/208 (0.034) 3/80 (0.038) yes no (0.01)
2020A > G c.1792A > G T598A G 4/208 (0.019) 0/80 (0.000) yes no (?)
2457T > C c.2229T > C H743H C 18/380 (0.047) 5/80 (0.063) yes no (?)
3199A > G c.2971A > G N991D G 7/208 (0.034) 3/80 (0.038) yes no (?)
3624A > G c.3396A > G L1132L G 73/208 (0.35) 38/80 (0.48) yes no (0.31)
4035T > C c.3807T > C V1269V C 27/208 (0.130) 18/80 (0.225) yes no (0.19)
4486G > T c.4258G > T D1420Y T 3/208 (0.014) 0/80 (0.000) yes no (?)
5427C > T c.5199C > T S1733S T 4/208 (0.019) 4/80 (0.050) yes no (?)
7470A > G c.7242A > G S2414S G 57/208 (0.27) 21/80 (0.26) yes no (0.21)
8034-14C > T c.7806-14C > T intron T 95/208 (0.46) 33/80 (0.41) yes no (0.50)
8410G > A c.8182G > A V2728I A 1/208 (0.005) 1/80 (0.013) yes no (?)
10323delCins11 10095delCins11 3369X del 3/380 (0.008) 0/80 (0.000) yes no (?)
Description of nucleotide variations is in accordance with BIC nomenclature* (DNA variants are numerated according to NCBI reference sequence HSU14680 for
mRNA of BRCA1,or U43746 for mRNA of BRCA2; the first nucleotide of mRNA is numerated as 1) or HGVS nomenclature** (DNA variants are numerated according
to NCBI reference sequence NM_007294.2 for BRCA1, NM_000059.3 for BRCA2; the first nucleotide of the start codon ATG is numerated as 1). UTR - untranslated
region. (?)-data unknown.
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in the Italian population, 43% in the Spanish population,
and 52% in the Dutch population [15,17,23,25].
However, with the additional subdividing of groups in
our study, even higher mutation detection rate (of 85%)
was observed in the subgroup of families with two or
more ovarian cancers and only one breast cancer (Sub-
group - more O+1B). On the other hand, the proportion
of detected mutations in BRCA1 and BRCA2 genes fell
to 36% when we investigated the subgroup of families
with at least two ovarian cancers and no breast cancer
in their family history (Subgroup - only O)( T a b l e7 ) .
Similar findings were perceived by Ramus et al. In their
studies, the frequency of BRCA1 and BRCA2 mutations
in the families with site-specific ovarian cancer was
lower than in the families with breast and ovarian can-
cer. The families with three or more ovarian cancers
and at least one breast cancer had mutations in BRCA1
and BRCA2 in 81% of cases (similar to our results)
while in the families with three or more ovarian cancers
and no breast cancer mutations in BRCA1 or BRCA2
were detected in only 63% (which is still much higher
than in our study) [34,35]. In the Dutch population, the
mutation detection rate in the families with at least two
ovarian cancers and one or more breast cancers was
82%, whereas in the families with only ovarian cancer
history, it was 36%, which is quite similar to our detec-
tion rates [17].
This lower mutation detection rate in the families with
ovarian cancers only indicates the existence of other
(different from BRCA1/2) predisposing genes in
hereditary ovarian cancers [36]. It is well known that
hereditary ovarian cancer can be associated also with
Lynch syndrome and with mutations in mismatch repair
genes [35].
If we gather all families with at least two breast can-
cers in their family history regardless of the age at the
disease onset and no ovarian cancer, the mutation
detection rate in the Slovenian population is 24%. For
comparison, the mutation detection rate for BRCA1 and
BRCA2 in similar groups of families in the Dutch,
German, Italian and Spanish population is 13%, 24%,
18.5% and 15%, respectively [15,17,23,25]. In the families
with two or more breast cancer cases and at least two of
them diagnosed under the age of 50 and no ovarian
cancer (Group A), the mutation detection rate for
BRCA1 is 23% and for BRCA2 is 13% or 36% for both
genes in the Slovenian population, 27% in the Dutch
population and 37% in the German population [15,17].
In the group of families with no ovarian cancer but at
least two or more breast cancer cases with only one of
them diagnosed before the age of 50 (Group C), the
mutation detection rate for BRCA1 was 11% and for
BRCA2 8% or 19% for both genes. These detection rates
are slightly higher than the detection rates reported by
the German study group (7% and 3% for BRCA1 and
BRCA2, respectively) [15]. In the Dutch population, the
mutation detection rate for both BRCA1 and BRCA2 in
this group of families was 15% [17].
When considering our families with at least two breast
cancers and all of them diagnosed after age of 50 and no
ovarian cancer (Group D), the mutation detection rate
Table 4 Unclassified sequence variants in BRCA1 gene in Slovenian population
BIC
nomenclature*
HGVS
nomenclature**
Protein
change
Allele No. of alleles/all alleles
of tested probands
(allele frequencies)
No. of alleles/all alleles of
tested healthy individuals
(allele frequencies)
Described
in BIC
database
Clinical
importance
entered in BIC
database
Missense changes
212C > G c.93C > G I31M G 3/380 (0.008) 0/80 (0.000) yes unknown
462C > A c.343C > A P115S A 1/208 (0.005) 0/80 (0.000) no
1112G > C c.993G > C R331S C 2/208 (0.010) 0/80 (0.000) yes unknown
3238G > A c.3119G > A S1040N A 5/208 (0.024) 0/80 (0.000) yes unknown
3421G > A c.3302G > A S1101N A 1/208 (0.005) 0/80 (0.000) yes unknown
3573G > A c.3454G > A D1152N A 1/208 (0.005) 0/80 (0.000) yes unknown
3768T > C c.3649T > C S1217P C 1/208 (0.005) 0/80 (0.000) no
4158A > G c.4039A > G R1347G G 2/208 (0.010) 0/80 (0.000) yes unknown
4384G > A c.4265G > A G1422E A 1/208 (0.005) 0/80 (0.000) no
4675A > G c.4556A > G N1519S G 1/208 (0.005) 0/80 (0.000) no
5075G > A c.4956G > A M1652I A 3/208 (0.014) 0/80 (0.000) yes unknown
5124G > T c.5005G > T A1669S T 1/208 (0.005) 0/80 (0.000) yes unknown
Description of nucleotide variations is in accordance with BIC nomenclature* (DNA variants are numerated according to NCBI reference sequence HSU14680 for
mRNA of BRCA1; the first nucleotide of mRNA is numerated as 1) or HGVS nomenclature** (DNA variants are numerated according to NCBI reference sequence
NM_007294.2 for BRCA1; the first nucleotide of the start codon ATG is numerated as 1). UV- unclassified variant.
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Page 7 of 11was 5% (only one mutation discovered in BRCA2). In the
Dutch population, the reported mutation detection rate
in similar group of families was 6% and for the German
population 10% [15,17]. Since the mutation detection
rate in the families with the same number of breast can-
cer cases is higher in the group with earlier disease onset
(Group A) than in the groups with later disease onset
(Groups C and D), the age at the disease onset seems to
influence the BRCA1/2 mutation detection rate (Table 8).
A rather low mutation detection rate in the group with
breast cancers diagnosed at the age over 50 years sug-
gests that other potential predisposing genes confer an
increased risk of postmenopausal breast cancer [37].
The families with a single male breast cancer case and
no other breast/ovarian cancers among first degree rela-
tives (Group MBR) had the mutation detection rate of
Table 5 Unclassified sequence variants in BRCA2 gene in Slovenian population
BIC
nomenclature*
HGVS
nomenclature**
Protein
change
Allele No. of alleles/all alleles
of tested probands
(allele frequencies)
No. of alleles/all alleles of
tested healthy individuals
(allele frequencies)
Described
in BIC
database
Clinical
importance
entered in BIC
database
Missense changes
2032G > A c.1804G > A G602R A 1/208 (0.005) 0/80 (0.000) yes unknown
3747C > T c.3519C > T S1152L T 1/208 (0.005) 0/80 (0.000) no
5078G > A c.4850G > A S1617N A 1/208 (0.005) 0/80 (0.000) no
5972C > T c.5744C > T T1915M T 14/208 (0,067) 3/80 (0.038) yes unknown
8107A > T c.7879A > T I2627F T 1/380 (0.003) 0/80 (0.000) yes unknown
8482A > T c.8254A > T I2752F T 1/208 (0.005) 0/80 (0.000) yes unknown
8579G > A c.8351G > A R2784Q A 2/380 (0.005) 0/80 (0.000) yes unknown
9133G > A c.8905G > A V2969M A 2/380 (0.005) 0/80 (0.000) yes unknown
9599A > T c.9371A > T N3124I AT 1/380 (0.003) 0/80 (0.000) yes unknown
10462A > G 10234A > G I3412V G 1/208 (0.005) 0/80 (0.000) yes unknown
Frameshift changes
4091delTAA c.3863delTAA del288N del 2/208 (0.010) 0/80 (0.000) no
9512dupl12 c.9284_9295dup12 dup 1/380 (0.003) 0/80 (0.000) no
Intron changes
IVS2-7A > T c.68-7A > T intron T 1/208 (0.005) 1/80 (0.013) yes unknown
Synonymous changes
1395G > A c.1167G > A P389P A 1/208 (0.005) 0/80 (0.000) no
1977G > A c.1749G > A L583L A 1/208 (0.005) 0/80 (0.000) no
4296G > A c.4068G > A L1356L A 3/208 (0.014) 0/80 (0.000) yes unknown
5013G > A c.4785G > A Q1595Q A 1/208 (0.005) 0/80 (0.000) no
5985G > A c.5757G > A L1919L G 0/208 (0.000) 1/80 (0.013) no
10338G > A 10110G > A R3370R A 2/380 (0.005) 0/80 (0.000) yes unknown
10431G > A 10203G > A T3401T A 1/208 (0.005) 0/80 (0.000) no
Description of nucleotide variations is in accordance with BIC nomenclature* (DNA variants are numerated according to NCBI reference sequence U43746 for
mRNA of BRCA2.; the first nucleotide of mRNA is numerated as 1) or HGVS nomenclature** (DNA variants are numerated according to NCBI reference sequence
NM_000059.3 for BRCA2; the first nucleotide of the start codon ATG is numerated as 1).
Table 6 Incidence of BRCA1 or BRCA2 mutations among different groups of Slovenian families defined according to
family history
Group A B C D E MBR
No. of mutation positive families (%)*
BRCA1 positive 18/77 (23%) 42/100 (42%) 8/75 (11%) 0/21 (0%) 2/24(8%) 0/25 (0%)
BRCA2 positive 10/77 (13%) 8/100 (8%) 6/75 (8%) 1/21 (5%) 0/24(0%) 1/25 (4%)
*number of positive families/number of all tested families in the group (the proportion of positive families). Group A - families with two or more cases of breast
cancer including at least two cases with the disease onset under the age of 50 and with no ovarian cancer. Group B - families with one or more cases of breast
and at least one ovarian cancer. Group C - families with two or more cases of breast cancer including one case diagnosed before the age of 50 and with no
ovarian cancer. Group D - families with two or more cases of breast cancer all of them diagnosed beyond the age of 50 and with no ovarian cancer. Group E -
families with a single case of breast cancer diagnosed at the age under 40 years. Group MBR - families with a single male breast cancer. Bilateral breast cancers
were considered as two separate cases of cancer.
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together, all families with male breast cancer in their
family history had the mutation detection rate of 11.5%
(3 positive families from 26 tested families) [38]. The
mutations detected in male breast cancer were c.7806-2A
> G and c.3975_3978dupTGCT in BRCA2 gene. In com-
parison, the mutation detection rates in the families with
male breast cancer in the German population were 25%,
(12 positive cases from 47 tested families) and as high as
42% in Italian (3 positive cases from 7 tested families)
and in the Dutch population (5 positive cases from 12
tested families), which is much higher than in our popu-
lation [15,17,25]. In this place, it must definitely be
stressed that, in our study, not all samples of male breast
cancer have been fully screened up till now and that only
tests for the most frequent mutations in the Slovenian
population have been performed. This might be one of
the possible reasons for a lower mutation detection rate
in this group of families in our population.
Nevertheless, a low detection rate has also been per-
ceived in another group of families with a single case of
female breast cancer (Group E) where the mutation
detection rates for BRCA1 and for BRCA2 were 8% and
0%, respectively. In the German population, the detec-
tion rates in this group are reported to be 8% in BRCA1
and 4% in BRCA2 [15].
T h em a j o r i t yo fc o m m o nm u t a t i o n si nBRCA1
(c.181T > G, c.1687C > T, c.5266dupC) observed in
the Slovenian population have been frequently
described also in other European populations (Table 1),
but not the mutation c.844_850dupTCATTAC. This
mutation has been previously described only twice in
the German population, while it was found in as many
as 8 families in the Slovenian population. Another rare
mutation in BRCA1 - the mutation c.181T > A has also
been previously described only in the Slovenian popula-
tion [39].
In BRCA2, the most frequent mutations were c.7806-
2A > G, c.5291C > G and c.3975_3978dupTGCT. The
mutation c.7806-2A > G has been already reported by
our group [31]. It is a Slovenian founder mutation,
reported before also by others [15,40,41]. The mutation
c.5291C > G, however, according to BIC database, has
not been described in any other populations, other then
the Slovenian one.
Different mutations in BRCA1 and BRCA2 genes have
a different penetrance for breast and for ovarian cancer
[35]. This has been observed also in our population.
The families affected by one mutation actually differ
from the families affected by another mutation by
means of the proportion of ovarian cancers among all
breast and ovarian cancers in the family. These differ-
ences can be due to the variations in the biology of the
translated protein having a different effect on the nor-
mal breast or ovarian tissue. The difference could also
be associated with other than BRCA1 and BRCA2 com-
mon moderate/low penetranceg e n e si nt h ep o p u l a t i o n
[35,42,43].
Table 7 Incidence of BRCA1 or BRCA2 mutations among different sub-groups of Slovenian families with breast and
ovarian cancer
Sub-group BA BC BD 1B+1O MoreO+1B Only O
No. of mutation positive families (%)*
BRCA1 positive 10/19 (53%) 14/21 (67%) 2/7 (29%) 8/32 (25%) 6/7 (86%) 4/14 (29%)
BRCA2 positive 1/19 (5%) 2/21 (10%) 2/7 (29%) 3/32 (9%) 0/7 (0%) 1/14 (7%)
*number of positive families/number of all tested families in the group (the proportion of positive families). Group B (families with one or more cases of breast
and at least one ovarian cancer) was further subdivided into sub-groups: BA - families with at least one ovarian cancer and at least two breast cancers diagnosed
under the age of 50; BC - families with at least one ovarian cancer and at least two breast cancers, one of them diagnosed under the age of 50; BD - families
with at least one ovarian cancer and at least two breast cancers all of them diagnosed beyond the age of 50; 1B+1O - families with only one ovarian cancer and
one breast cancer in the family or only one affected individual in the family, but having both types of cancer at the same time; more O+1B - families with at
least two ovarian cancers and only one breast cancer; only O - families with at least two ovarian cancers and no breast cancer.
Table 8 Incidence of BRCA1 or BRCA2 mutations among Slovenian families with only breast cancer history (no ovarian
cancer) subdivided according to the number of breast cancer cases in the family
Group 2 breast cancers in family
history*
3 breast cancers in family
history*
4 breast cancers in family
history*
more then 5 breast cancers in family
history*
A 9/29 (31%) 5/21 (24%) 7/16 (43%) 7/11 (64%)
C 5/37 (13%) 3/25 (12%) 4/9 (44%) 2/4 (50%)
D 1/10 (10%) 0/6 (0%) 0/5 (0%) 0/0
*number of positive families/number of all tested families in the group (the proportion of positive families). Group A - families with two or more cases of breast
cancer including at least two of them diagnosed under the age of 50 and with no ovarian cancer. Group C - families with two or more cases of breast cancer
including one case diagnosed before the age of 50 and with no ovarian cancer. Group D - families with two or more cases of breast cancer all of them
diagnosed beyond the age of 50 years and with no ovarian cancer.
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With the introduction of the genetic councelling and
testing into clinical oncology the approach to individuals
and families at elevated risk for specific cancer changed
radically. It offers namely not only the identification of
individuals at risk but also planning of different preven-
tion strategies that may reflect in longer life expectan-
cies of these individuals. In our study, 96 families
bearing the BRCA1 or BRCA2 mutation were identified.
The mutation detection rates for BRCA1 and BRCA2
genes in different groups of families with different family
history were similar to the mutation detection rates in
other European populations. The most common muta-
tions in the BRCA1 gene in the families with an
increased risk of breast and/or ovarian cancer in Slove-
nia are c.181T > G, c.1687C > T, c.5266dupC,
c.844_850dupTCATTAC and c.181T > A. The most fre-
quent mutations in BRCA2 are c.7806-2A > G, c.5291C
> G and c.3975_3978dupTGCT. The cumulative share
of these frequent mutations in BRCA1 and BRCA2
genes in Slovenian families affected with mutations is
68.7%. In the Slovenian population, the mutation detec-
tion rate seems to be influenced by the presence of
ovarian cancer history, the age at the diagnosis of breast
cancers in the family and the number of breast cancer
cases in the family. As well, the mutation detection rate
might further be influenced in the future - it might
namely increase when the character of some of the
unclassified variants will be clarified as pathogenic.
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